Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis

Sci Rep. 2020 Nov 23;10(1):20397. doi: 10.1038/s41598-020-77524-x.

Abstract

COVID-19 caused by the SARS-CoV-2 is a current global challenge and urgent discovery of potential drugs to combat this pandemic is a need of the hour. 3-chymotrypsin-like cysteine protease (3CLpro) enzyme is the vital molecular target against the SARS-CoV-2. Therefore, in the present study, 1528 anti-HIV1compounds were screened by sequence alignment between 3CLpro of SARS-CoV-2 and avian infectious bronchitis virus (avian coronavirus) followed by machine learning predictive model, drug-likeness screening and molecular docking, which resulted in 41 screened compounds. These 41 compounds were re-screened by deep learning model constructed considering the IC50 values of known inhibitors which resulted in 22 hit compounds. Further, screening was done by structural activity relationship mapping which resulted in two structural clefts. Thereafter, functional group analysis was also done, where cluster 2 showed the presence of several essential functional groups having pharmacological importance. In the final stage, Cluster 2 compounds were re-docked with four different PDB structures of 3CLpro, and their depth interaction profile was analyzed followed by molecular dynamics simulation at 100 ns. Conclusively, 2 out of 1528 compounds were screened as potential hits against 3CLpro which could be further treated as an excellent drug against SARS-CoV-2.

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Antiviral Agents / pharmacology*
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Cheminformatics / methods*
  • Coronavirus 3C Proteases / antagonists & inhibitors
  • Deep Learning*
  • Drug Evaluation, Preclinical / methods
  • Drug Repositioning / methods*
  • HIV-1 / drug effects*
  • Humans
  • Infectious bronchitis virus / drug effects
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation*
  • Protease Inhibitors / pharmacology*
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / enzymology

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • Protease Inhibitors
  • Coronavirus 3C Proteases